Autoantibodies to double-stranded (ds) DNA are an important diagnostic marker and pathogenic factor for systemic lupus erythematosus (SLE). Identifying dsDNA mimotopes is a way to discover diagnostic and therapeutic candidates for SLE. 'Mono-specific' SLE anti-dsDNA antibodies were obtained by affinity purification using dsDNA-coupled Sepharose column. Using the anti-dsDNA antibodies to screen a phage peptide library, we were able to identify a mimotope that has a motif peptide sequence of RLTSSLRYNP. This chemically synthesized peptide could be recognized by 88% (37 out of 42) of anti-dsDNA antibody-positive SLE sera with a cut-off point at mean ⍣ 3 SD of the negative control sera at OD 492 . The reaction of the peptide with SLE sera in ELISA was highly correlated with that of dsDNA (r ⍧ 0.809, P Ͻ 0.0001). Of particular interest, not only dsDNA but also single-stranded (ss) DNA and native RNA could inhibit the binding of the peptide with SLE sera, suggesting that the mimotope is shared by ds and ssDNAs as well as native RNA, whereas denatured RNA was not observed to inhibit the binding. The peptide was also able to elicit an immune response in rabbits and the anti-peptide rabbit serum was observed to cross-react with the peptide, ss and dsDNAs, and ss and dsDNAs could inhibit the binding of the anti-peptide serum and the peptide. However, the inhibition was not obtained with RNA. Our findings demonstrate the potential of the peptide mimic in diagnostic tests of SLE, and in the investigation of anti-DNA antibody origin and of DNA-anti-DNA antibody interaction.
Introduction
Autoimmune diseases are characterized by autoantibodies bodies and immune complex, which eventually leads to tissue damage. Since 1957, the antinuclear antibody (ANA) test had against a diverse range of self-antigens. Although the patterns of autoantibody have been considered as reflecting the been one of the most important tests used to evaluate patients for the presence of connective tissue disorders (1) . The ANA immunopathological processes of the autoimmune disease, in many cases the precise contribution of the autoantibodies screening test detects primarily a group of antibodies against the nuclear antigens that are present in abundance, e.g. to the actual pathology is not known. Therefore, for a long time, the autoantigen and autoantibody approach had been double-stranded (ds) DNA, Sm, nuclear ribonucleoprotein, SSA and SSB. Among them, the anti-dsDNA test is the the key points for the elucidation of the autoimmune pathological processes, and in seeking proper diagnostic/therapeutic most widely used serological hallmark for SLE, and its titer correlates positively with disease activity in both humans and procedures.
Systemic lupus erythematosus (SLE) is an autoimmune mice. Moreover, antibodies to dsDNA are not only a diagnostic marker but also a pathogenic factor for SLE. A number of rheumatic disease characterized by the deposition of autoanti-studies have shown that anti-DNA antibodies cross-react with wash buffer. Horseradish peroxidase-conjugated anti-human IgG (raised in goat) was then added and incubated for a variety of antigens, including intracellular and extracellular components (2-4). Thus, direct binding of anti-DNA antibodies another 30 min at room temperature. The wells were then emptied, washed and colored by adding 3,3Ј,5,5Ј-tetramethylto glomerular basement membrane was suggested as the major step in the development of glomerulonephritis (5). On benzidine (TMB) chromogen. After stopping the color reaction by adding 100 µl of ELISA stopping solution to each well, the other hand, although reports have demonstrated that anti-DNA antibodies have the characteristics of antibodies arising absorbance was read at 450 nm with a reference wavelength 620 nm. from an antigen-selected immune response (6-8), the actual role of DNA in eliciting the production of anti-DNA antibodies Preparation of dsDNA-coupled CNBr-activated Sepharose is not yet clear. It remains uncertain which antigen triggers column the production of these antibodies.
The technology of phage-displayed random peptide librarCNBr-activated Sepharose 4B gel was purchased from Pharmacia (Uppsala, Sweden). The protocol provided by the ies (RPL) (9-11) has recently become a powerful technique for elucidating protein-protein/peptide interactions. Many manufacturer for treatment of the gel and for coupling of protein to the gel was used. Briefly, 1.5 g of the gel was publications have already shown the potency of this procedure by establishing the binding characteristics between antigensoaked in 50 ml of 1 mM HCl for at least 30 min at room temperature and allowed to swell. The swollen gel was then antibody, signaling molecule-receptor and substrateenzyme. In particular, this technology offers a number of washed 3 times with about 300 ml 1 mM HCl by suspending the gel in a beaker and filtering the gel suspension in a flask. advantages in the research area of autoimmune diseases. Firstly, the RPL screening method can be used to map any Human placenta dsDNA (Sigma, St Louis, MO) was dissolved in 1ϫSSC (150 mM NaCl/15 mM sodium citrate, pH 7.0) at a epitope (mimotope) without prior knowledge of the protein antigen. Secondly, since several reports have shown that concentration of 3 mg/ml and further diluted in coupling buffer (0.1 M Na 2 CO 3 /0.5 M NaCl, pH 8.3) to 0.5 mg/ml. The dried polyclonal antibodies could be used as screening ligates, this means that autoimmune patient sera could be used as a gel was resuspended in 6 ml of this dsDNA solution and incubated at 4°C overnight with constant rotation to keep the source for isolating screening ligates, thus providing a unique advantage of linking the RPL approach to a disease-related gel in suspension (~2 mg of dsDNA was retained with the gel by measuring the difference of OD 260 before and after antigenic structure directly.
We present here the application of RPL in searching a the incubation). After washing away the unbound dsDNA with coupling buffer, the gel was resuspended in 0.1 M Tris-HCl, peptide mimic of dsDNA antigenic structure by using antidsDNA antibodies obtained from SLE patient sera. We have pH 8.0 and incubated for 2 h at room temperature to block the uncoupled area. After the blocking incubation, the gel successfully identified a peptide motif which could mimic the antigenicity of native human placenta dsDNA. Investigations was successively washed with acetate buffer (0.1 M sodium acetate, 0.5 M NaCl), pH 4.0 followed by 0.1 M Tris-HCl, pH in specificity revealed that this structure was shared by denatured human placenta single-stranded (ss) DNA, natural 8.0 (3 times), with 10 mM Tris, pH 7.5 (at least 8 times), with 0.1 N HCl-glycine, pH 2.5 (at least 8 times), with 0.1 M phage genomic ssDNA and native calf liver RNA. Moreover, when the peptide was used to immunize rabbits, the harvested triethylamine, pH 11.5 (at least 8 times) and finally with 10 mM sodium phosphate buffer, pH 7.0 until the pH of filtrate was anti-peptide rabbit serum could not only recognize the peptide itself, but also ss and dsDNAs.
7.0. The gel was then packed into a chromatography column (Pharmacia) and kept at 4°C for use.
Preparation of the screening ligate Methods
The preparation of screening ligate has been described Human sera elsewhere (12), but with some modifications in this study. Briefly, 1 ml of pooled positive sera was loaded on a Human sera used in this study were collected from SLE patients and non-SLE controls at National University Hospital, GammaBind Sepharose (Pharmacia) column. After incubating for 30 min at room temperature, the column was washed to Singapore. All of 42 female SLE patients and 40 female non-SLE controls satisfied American College of Rheumatology remove unbound fractions with 0.1 M sodium phosphate buffer, pH 7.0 until the baseline reached zero. The bound (formerly American Rheumatology Association) revised criteria for the classification of SLE (1). The age of the SLE IgG fraction was then eluted with 0.5 M acetic acid, pH 2.7 and neutralized immediately with 2 M Tris. The IgG-containing patient group ranged from 15 to 69 years with an average of 40 years. The control sera were from dengue fever patients fractions were then pooled together and dialyzed against 10 mM phosphate buffer, pH 7.0. Subsequently, the 'monoranging in age from 10 to 60 years with an average of 36 years.
The presence and absence of antibodies to dsDNA in the specific' anti-dsDNA fraction was purified using the human placenta dsDNA-coupled CNBr-activated Sepharose 4B gel SLE sera and control sera were assayed by the QUANTA Lite dsDNA ELISA test kit (INOVA Diagnostics, San Diego, CA).
column prepared as described above. The column was washed extensively with washing buffer (10 mM sodium The assay procedures provided by the manufacturer were followed. Briefly, each serum was diluted 1:100 with sample phosphate, pH 7.0) overnight before use. The dialyzed IgG fraction was then loaded onto the affinity column and incubdiluent and introduced into dsDNA-coated ELISA microtiter wells (100 µl/well) in duplicate. After incubating for 30 min at ated for 30 min at room temperature. After incubation, the unbound IgG fraction was washed away with the washing room temperature, the wells were emptied and washed with buffer, while the bound IgG was eluted with 0.1 M sodium were then removed and the wells were washed 3 times with 0.5ϫTBST. This was followed by incubation with biotinylated phosphate buffer, pH 7.0. The affinity-purified anti-dsDNA IgG was dialyzed for 4 h against 0.1 M sodium borate buffer, anti-fd phage antibodies (Sigma) diluted with Blotto at a ratio of 1/1000 for 2 h at 37°C. After another round of extensive pH 8.8 and biotinylated subsequently by the succinimide method (13).
washing, horseradish peroxidase-conjugated streptavidin (Sigma), 1/1000 diluted with Blotto, was then added and Biopanning of phage-displayed RPL by anti-dsDNA antiincubated for 1 h at 37°C. Finally, following another washing bodies step, the plates were treated with o-phenylenediamine dihydrochloride (OPD) for color development. Absorbance A 15mer peptide library displayed on gene VIII product of fd phage (14) was used in this study. This library was generously was measured at 492 nm using 620 nm as reference wavelength in an ELISA reader (Dynex, Middlesex, UK). provided by Professor G. P. Smith (University of Missouri, Columbia, MO) The basic methods of screening were adapted Selection of anti-dsDNA antibody-reactive phage clones. from the procedures as described before (12,15). Three Phage supernatants prepared as described above were rounds of screening were performed with the biotinylated added to the wells (100 µl/well) of the ELISA selection plates anti-dsDNA antibodies. For the first round of selection, 10 µg and allowed to bind for 2 h at 37°C. The subsequent treatments of biotinylated anti-dsDNA antibodies in 400 µl of 0.5ϫTBST for ELISA assay were exactly the same as described above. (25 mM Tris, 75 mM NaCl and 0.05% Tween 20, pH 7.5)
A phage clone bearing a 15mer phagotope DLHRYSWKcontaining 1 mg/ml dialyzed BSA were immobilized onto a TQGDDRE selected previously from the 15mer phage library streptavidin-coated Petri dish by incubation for 2 h at room by mAb MAb47 which is specific for dengue virus NS1 protein temperature. In subsequent rounds of selection, 1 µg of (unpublished data) was processed in parallel as a negative biotinylated anti-dsDNA antibodies was used. To saturate the control and its reading was referenced as background bindbiotin binding sites on the dish, 4 µl of 10 mM free biotin was ing. Those phage clones showing more than twice the reading added and incubated for 1 h at room temperature. The of background binding at 492 nm were selected as positive unbound antibodies and biotin were removed by washing 6 clones. times with 0.5ϫTBST. Phage suspensions (5 µl of library for the first round and 100 µl of output phages for the second DNA sequencing and third rounds and 4 µl of 10 mM biotin in 400 µl of Clarified culture supernatants of positive clones selected as 0.5ϫTBST) were added and incubated for 4 h at room mentioned above were transferred to new Eppendorf tubes temperature. After the removal of unbound phages by washing and the phages were recovered by 20% (w/w) PEG/NaCl 10 times with 0.5ϫTBST, the bound phages were recovered solution (16.7%/3.3 M). After incubation for 4 h at 4°C, phages using elution buffer (0.1 N HCl-glycine, pH 2.2, 1 mg/ml were pelleted at 10,000 g for 10 min. The phage pellets were BSA, 0.1 mg/ml phenol red). The eluates were immediately then re-suspended in 100 µl of TBS. Viral DNA was extracted neutralized using 2 M Tris. from 30 µl of phage suspension with phenol/chloroform/water Eluted phages were amplified in Escherichia coli K91Kan solution. DNA in the aqueous layer was then precipitated by and used as input in the subsequent rounds of selection.
ethanol and used as a template for cycling sequencing with After three rounds of selection, phage clones harvested the primer: 5Ј-CTGAAGAGAGTCAAAAGC-3Ј. The sequenfrom the third round output were randomly selected and cing was carried out in an automated DNA sequencer (model propagated in 1.5 ml of terrific broth [1.2% (w/v) bacto-373) from Perkin-Elmer Applied Biosystems (Foster City, CA). tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol, 17 mM
The amino acid sequences of the inserts were deduced from KH 2 PO 4 and 72 mM K 2 HPO 4 ] supplemented with 20 µg/ml the DNA sequences. tetracycline at 37°C for 20 h. The cultures were clarified at 2500 g for 10 min, and the supernatants were recovered for Peptide synthesis the selection of anti-dsDNA antibody binding clones and Peptides were synthesized by Fmoc chemistry using an eightsubsequent DNA sequencing.
branched multiple antigen peptides (MAP) resin. Fmoc amino Test of biopanning enrichment and selection of phage clones acids and MAP resins were purchased from Bachem (San reactive with anti-dsDNA antibodies by ELISA assay Jose, CA) and AnaSpec (Torrance, CA). Peptide synthesis was carried out in our laboratory in an automatic peptide Preparation of ELISA plates. ELISA microtiter wells were synthesizer, model 433A (Perkin-Elmer Applied Biosystems). coated overnight at 4°C with 100 µl/well affinity-purified anti-
The motif peptide MAP-RLTSSLRYNP and a control peptide dsDNA antibodies at a concentration of 5 µg/ml in coating MAP-TLPNRSYLSR that is a randomly scrambled sequence buffer (50 mM NaHCO 3 , pH 9.6). After incubation, the wells of the motif peptide sequence were synthesized. The purity were washed 3 times with 0.5ϫTBST and blocked with Blotto of the peptides was ജ90% checked by reverse-phase HPLC (5% skimmed milk in 0.5ϫTBST) for 60 min at 37°C. After and the compositions were confirmed by amino acid analysis. washing again, the well strips were stored at 4°C for use.
Serum binding to synthetic peptides Test of biopanning enrichment.
Phages from the library and the output phages of three rounds were diluted with Blotto to Motif peptide MAP-RLTSSLRYNP was first dissolved in DMSO at a concentration of 100 mg/ml (w/v) and then diluted to 1ϫ10 11 transducing units (TU)/ml. The phage suspensions were introduced into the anti-dsDNA antibody-coated microt-10 mg/ml with water (stock solution). The stock solution was further diluted 100 times with coating buffer to 0.1 mg/ml iter wells and incubated for 2 h at 37°C. The unbound phages for coating ELISA microtiter wells. Control peptide MAP-TLPNRSYLSR was dissolved in coating buffer at a concentration of 0.1 mg/ml. The peptide solutions were added to microtiter wells (100 µl/well) and incubated at 4°C overnight. The wells were washed and blocked with Blotto. The sera diluted 1/100 with Blotto were added to the peptide-coated wells and incubated for 2 h at room temperature. After washing, horseradish peroxidase-conjugated anti-human IgG was added and incubated for 1 h at room temperature. The plates were then washed and colored by OPD chromogen as described above. Human placenta DNA, ss fd phage genomic DNA and calf dsDNA after affinity purification. Anti-dsDNA antibody reactivities in liver RNA were 2-fold serially diluted starting from 400 µg/ml. total serum IgG before affinity purification (BP), and in the unretained fd phage DNA was extracted using ssPHAGE DNA Spin kit fraction (UF) and in retained fraction (RF) after affinity purification were compared by ELISA assay on QUANTA Lite dsDNA plates (0.5 (BIO101, La Jolla, CA), and the other two DNA and RNA were µg of IgG/well). The anti-dsDNA antibody reactivity was highly purchased from Sigma. A set of dilutions of human placenta enhanced after affinity purification.
Competitive binding inhibition assay
DNA and a set of dilutions of calf liver RNA were heated at 95°C for 3 min and rapidly cooled on ice to obtain denatured ssDNA and RNA. To be comparable, all dilutions of DNAs and RNAs were cooled on ice before mixing equally in rabbit IgG, 1/1000 diluted with Blotto, was added and incubvolume with a cold dilution of a panel of SLE sera. The final ated for 30 min at room temperature. The wells were washed, concentrations of DNAs and RNAs were from 200 to and colored by OPD chromogen and absorbance was meas-0.39 µg/ml and the dilution of SLE sera was 1/100. After ured as described above. mixing together, they were left at 4°C for 2 h and then
To demonstrate the specificity of anti-peptide serum, comtransferred to a motif peptide-coated ELISA plate in duplicate petitive binding inhibition ELISA assay was also performed (100 µl/well) for 30 min at 4°C. After subsequent incubation with anti-peptide rabbit serum and the inhibitors DNAs and with horseradish peroxidase-conjugated anti-human IgG for
RNAs as with SLE sera described above. The experiment 30 min at room temperature, the plates were processed as and the concentrations of inhibitor DNAs and RNAs remained described above. The percentage inhibition of sera binding the same, but the final dilution of anti-peptide serum was to peptide by the inhibitors was calculated according to 1/300 in Blotto and the secondary antibody was horseradish the following equation: 100ϫ[1 -(OD 492 with inhibitorperoxidase-conjugated anti-rabbit IgG, 1/1000 diluted in background OD 492 )/(OD 492 without inhibitor -background Blotto. OD 492 )].
Immunization

Results
The immunization was performed by mixing equal volumes
The ligate and biopanning of Freund's adjuvant with peptide MAP-RLTSSLRYNP solution at a dose of 0.5 mg of peptide per injection. The emulsion Based on our previous observations (12,15), preparing the screening ligate as 'monospecific' as possible is the key step was injected s.c. at multiple points in the back region of the rabbits. Complete Freund's adjuvant was used in the first for a successful selection of target ligand(s) using RPL, especially when the screening ligates are polyclonal antibodinjection, whereas incomplete adjuvant was used in booster injections. Booster injections were carried out on days 14, ies. To obtain such 'monospecific' quality of screening ligate, SLE patient sera with anti-dsDNA antibodies were pooled 28, 42 and 56 after the first injection. Blood samples were taken before immunization and on the days when the booster and the IgG fraction was separated using a GammaBind column. The purified IgG was then subject to affinity purificainjections were performed. The last sample of serum was obtained on day 70.
tion with a Sepharose column coupled with human placenta dsDNA. After affinity purification, a commercial dsDNA ELISA ELISA binding reactivity and competitive inhibition assay of kit (QUANTA Lite) was applied to evaluate the specific reactivanti-peptide rabbit serum ity of anti-dsDNA antibodies. Figure 1 shows the specific ELISA reactivity of anti-dsDNA antibodies before and after Anti-peptide rabbit serum was tested for its ELISA binding reactivities with both motif and control peptide-coated plates affinity purification. When 0.5 µg of antibody protein was added to each well, a 5.16-fold increase in OD 492 (1.24/ and the QUANTA Lite ds and ssDNA ELISA plates. The rabbit sera taken before and after the peptide immunization were 0.24 ϭ 5.16) was observed. It was lower compared with that obtained previously with hyper-immune rabbit serum (12), 2-fold serially diluted with Blotto from 1/100 to 1/6400, and added to the peptide-and DNA-coated wells separately.
suggesting that the enhancement of specificity by affinity purification may vary depending on different ligate and ligand Each dilution was assayed in duplicate. The sera were allowed to bind for 1 h at room temperature. After washing away the and affinity-purification procedures. This purified anti-dsDNA antibody was biotinylated and used as ligate for screening. sera with 0.5ϫTBST, horseradish peroxidase-conjugated anti- Fig. 2 . Enrichment of phages reacted with anti-dsDNA antibodies by GHRYTSSVSLTEACP biopanning. After three rounds of biopanning, phage particles from From negative clones the phage library and the output of each round allowed to bind to SGTSHSASTTSKWFL affinity-purified anti-dsDNA antibody immobilized on microtiter plates NLLSVAPFWPLNDSL (1ϫ10 11 TU/well). Biotinylated anti-phage antibody and streptavidin-SDPDQWPFWRANEYG conjugated horseradish peroxidase were then applied to this ELISA assay. PL, 15mer phage library; 1st, first round of output; 2nd, second Motif residues are underlined. round of output; 3rd, third round of output. Phages with the specificity to anti-dsDNA antibody were enriched after three rounds of biopanning.
An important indication for a successful biopanning is the enrichment of phage clones reactive with screening ligates. We used an affinity ELISA to monitor the enrichment of anti-dsDNA antibody-binding phages. After three successive rounds of biopanning, a constant amount of phages (1ϫ10 11 TU), harvested from each round of biopanning, was added to the ELISA plate coated with purified anti-dsDNA antibodies. The result showed that phage clones that were reactive with anti-dsDNA antibodies were progressively enriched between rounds of biopanning (Fig. 2) . more than four residues to the motif sequence. Meanwhile, The means of OD readings of SLE sera bound to motif peptide and three negative clones that did not satisfy the criterion were control peptide were also very significantly different (P Ͻ 0.0001 by also selected and sequenced. They showed random
Selection of anti-dsDNA antibody-reactive phage clones and
Student's paired t-test).
sequences with no significant alignment with this motif.
Binding of SLE sera with motif peptide RLTSSLRYNP in ELISA
To test the presumed mimic structure, we chemically synthetested negative. The specificity of the motif peptide was demonstrated by ELISA assay. The motif peptide was reactive sized a peptide corresponding to the motif sequence RLTSSLRYNP and a control peptide TLPNRSYLSR. To with the SLE sera only but not with the control sera and the SLE sera were not reactive with the control peptide (Fig. 3) . increase binding reactivity with human sera, the peptides were synthesized as eight-branch MAP. The SLE sera and
The differences in means of OD 492 readings between the SLE sera and the control sera when they bound to motif peptide the control sera were tested by commercial QUANTA Lite ds and ssDNA ELISA kits. All of the sera in the SLE group were and between motif peptide and control peptide when they bound with SLE sera were statistically compared by Student's positive with antibodies to dsDNA while the control sera The 42 SLE sera were diluted 1/100 in Blotto and added in duplicate to motif peptide-coated plates and QUANTA Lite dsDNA plates separately. The reaction of SLE sera with motif peptide and dsDNA was assayed using ELISA. The ELISA reactivity of anti-dsDNA antibody with the peptide and dsDNA was highly correlated (r ϭ 0.809, P Ͻ 0.0001). The dots represent OD readings measured at 492 nm. sequence specific. It also demonstrated the specificity of the motif.
When ELISA readings of the SLE sera bound with the dsDNA-coated plates are plotted against the corresponding results of SLE sera bound with the motif peptide-coated plates, demonstrate. Denatured human placenta ssDNA, ss phage a close correlation in ELISA binding reactivity (correlation genomic DNA and calf liver RNA were used to demonstrate coefficient r ϭ 0.809, two-tailed probability P Ͻ 0.0001) was the specificity by inhibition ELISA assay. The results showed observed (Fig. 4) . This feature could make the motif peptide that the binding of SLE sera with motif peptide was also a diagnostic candidate for SLE.
inhibited by both denatured and natural ssDNAs, suggesting Binding of SLE sera with motif peptide was competitively that the motif peptide is also a ssDNA mimic. It is noteworthy inhibited by DNA and RNA that denatured human placenta ssDNA exerted more inhibition than the same concentrations of native human placenta Inhibition ELISA assay was carried out to investigate if the motif dsDNA, and natural ss phage genomic DNA exerted more peptide MAP-RLTSSLRYNP mimics an antigenic structure of inhibition than both human placenta ss and dsDNAs (Fig. 5 ). dsDNA and if the above demonstrated peptide-based binding One explanation for these results could be that more binding with SLE sera indeed mimics the binding property of dsDNA sites, normally masked by the dsDNA structure, are exposed with anti-dsDNA antibody. Human placenta dsDNA, which to the antibody after denaturation, and as phage genomic was used as ligand in affinity purification for screening ligate, DNA is a much smaller molecule than human placenta DNA, was used as inhibitor and the assay result showed that human phage ssDNA will give a higher molar concentration when placenta dsDNA inhibited the binding of anti-dsDNA antibody they are prepared at the same concentration (in w/v) and this with motif peptide (Fig. 5) . This inhibition effect suggests that possibly exhibits more biding sites to the antibody. Inhibition MAP-RLTSSLRYNP mimics an antigenic structure of dsDNA was also observed with native calf liver RNA, although not and the binding property of dsDNA with anti-dsDNA antibody.
high; however, interestingly, this inhibition disappeared after However, it has been indicated that the bulk of SLE antidenaturation of the RNA (Fig. 5) . The observations that RNA dsDNA antibodies are cross-reactive, they not only recognize inhibited the binding of anti-DNA antibody to DNA and the dsDNA but also ssDNA, and anti-dsDNA antibodies that bind ssDNA showed higher inhibition than dsDNA have been only dsDNA are relatively rare (16,17). Thus the specificity of motif peptide as a dsDNA mimic is an interesting feature to previously reported (18). 
Immunogenic motif peptide MAP-RLTSSLRYNP and anti-peptide serum
Since motif peptide MAP-RLTSSLRYNP showed highly sensitive and specific binding reactivity with SLE sera in ELISA, it is very interesting to demonstrate its antigenic and immunogenic properties on animals. If the motif peptide is indeed a mimic of dsDNA antigenic determinant, the antibody against this peptide should recognize both the peptide and dsDNA. Therefore, we used rabbits to demonstrate the immunogenicity of the motif peptide. The anti-peptide rabbit serum showed high ELISA binding reactivities with the motif peptide and also with dsDNA ( Fig. 6A and B) , suggesting that the peptide does mimic an antigenic determinant of dsDNA and this antigenic determinant is shared by ssDNA as mentioned above since the serum could also recognize ssDNA (Fig. 6B) .
On the other hand, the anti-peptide serum did not bind to the control peptide (Fig. 6A) , suggesting that the serum is specific for the motif peptide sequence. Inhibition ELISA assay was then performed to determine that the recognition of anti-peptide serum to DNA is indeed due to the same antigenicity of the peptide and DNA that drove the productive immunization. Native (ds) and denatured (ss) human placenta DNAs and ss phage genomic DNA were found to inhibit the binding of anti-peptide serum with the peptide, but both native and denatured calf liver RNAs were not (Fig. 7) , despite native calf liver RNA showing some investigate anti-dsDNA antibody binding structure from SLE patient sera with phage-displayed RPL. Firstly, it is of interest suggesting that the binding site occurs variably on both species of DNAs and the number of the binding site is not to investigate whether it is possible to identify peptide mimic(s) for a natural DNA molecule. Antibody to dsDNA is found in directly proportional to the length of DNA molecule. Another interesting finding is the inhibition on motif peptide and SLE the sera of 60-70% of SLE patients (17) and has thus served as an important marker for the diagnosis of this ailment. sera binding by native calf liver RNA. It has been reported that only anti-DNA antibodies eluted from the kidney of MRLAlthough not all anti-dsDNA antibodies are potentially pathogenic, it is found that some idiotypes, including human lpr/lpr mice bound with RNA, the antibodies in MRL-lpr/lpr mouse serum did not; moreover, the most characteristic polyclonal and monoclonal as well as murine monoclonal IgG anti-dsDNA and anti-ssDNA antibodies, are capable of feature of nephritogenic autoantibody was polyreactivity-the ability of individual antibodies to bind to multiple antigens binding to glomerular antigens, and formed immune deposits in vivo and in vitro (2) (3) (4) (5) . The formation of these deposits is (18). We did not address the inhibition by other autoantigens other than polynucleotide antigens in this study and the believed to be a key step in the renal damage of SLE patients. Therefore, defining the binding of anti-DNA antibodies to DNA pathogenic potential of the idiotypic anti-dsDNA antibodies that bind the motif peptide needs to be further investigated. in affinity, specificity and interaction mode is particularly important for understanding pathogenesis of SLE. The identi-
The potential of the motif peptide to be a drug candidate for SLE could be true only when the peptide binding anti-dsDNA fication of peptide mimics for dsDNA that are capable of inhibiting the binding of dsDNA with antibodies to dsDNA is antibodies are tested as a pathogenic idiotype. It is certain, however, that this peptide mimic provides us with a unique not only a potential drug discovery route for SLE, but also a valuable tool for studying the dsDNA-anti-dsDNA antibody opportunity to investigate the antigenic structure of DNA and the DNA-anti-DNA antibody interaction. complex. Recently, a peptide surrogate for dsDNA, which was able to inhibit the glomerular deposition of a murine
The origins of antibodies to DNA in SLE are not yet clear. Native mammalian DNA is poorly immunogenic and has never monoclonal anti-dsDNA antibody in vivo, has been identified from RPL using murine monoclonal anti-dsDNA antibodies as been found to be able to induce anti-DNA antibodies (25, 26) . Although some bacterial DNAs have been demonstrated to ligate (19). However, epitopes selected with murine mAb reflect the repertories of immune response of mouse rather be immunogenic in normal mouse, they do not elicit production of antibodies that cross-react with mammalian DNA (27, 28) . than human. Only antibodies in human sera are the natural response of human immune system to immunogens. ThereComplexes of ssDNA and Escherichia coli dsDNA noncovalently bound to a cationic protein such as methylated fore, epitopes selected by using patient sera as ligate would be a more direct and effective way for discovering the serum albumin have been reported to be able to induce antibodies with specificity only for ssDNA and Escherichia candidates of diagnostic and/or therapeutic agents. In fact, there is now an increasing trend in the use of disease-specific coli dsDNA respectively, but not for native mammalian DNA, and the complexes when prepared with mammalian dsDNA sera (20,21) and body fluids (22, 23 ) from patients in diseasespecific epitope mapping with RPL.
have not been immunogenic (29, 30) . Similarly, although anti-DNA antibodies produced after polyoma BK virus infection In this study, we have identified a peptide mimic for dsDNA using RPL and SLE patient sera. This peptide mimic, with and immunization were specific for native DNA, these induced anti-DNA antibodies were still different from autoimmune antithe sequence RLTSSLRYNP, exhibited a close correlation (correlation coefficient, r ϭ 0.809, P Ͻ 0.0001) with dsDNA DNA antibodies (31, 32) . Until recently, anti-dsDNA antibodies have been successfully induced by a complex of native calf in the binding reactivities with human serum antibody to dsDNA (Fig. 4) . This result suggests the possibility of using thymus DNA and a highly immunogenic DNA binding peptide, Fus1 (33) . The structural and functional characteristics of the the peptide mimic in the diagnosis of SLE. By using the peptide mimic in an ELISA format, it was established that induced anti-DNA antibodies were similar in all aspects to autoimmune anti-DNA antibodies (33, 34) . The common feaautoantibodies to dsDNA were detected in 37 of the 42 SLE ϩ sera (Fig. 3) . More importantly and interestingly, the peptide ture in these studies is that DNA seemed more immunogenic in non-autoimmune animals only when complexed with mimic was able to bind competitively SLE anti-DNA antibodies in vitro not only with dsDNA but also with ssDNA (Fig. 5) .
immunogenic protein and peptide. On the other hand, nevertheless, pneumococcal polyThese findings, on the one hand, suggest that the peptide mimic is an antigenic structure shared by both ss and saccharide antigens have been described to be able to elicit an immune response that produced some idiotypic antibodies dsDNAs, and, on the other hand, reflect that the motif peptide binding SLE anti-dsDNA antibodies are cross-reactive. This cross-reactive with DNA (35) . More recently, a peptide surrogate for dsDNA, which was identified from a phage peptide type of antigenic structures is believed to encompass exposed bases as well as the phosphodiester backbone (16,17). With library using a murine monoclonal anti-dsDNA antibody (19), has induced the production of anti-dsDNA antibodies in nonthe same spices of DNA, human placenta DNA, more binding structures were exhibited to the antibody on denatured ssDNA autoimmune BALB/c mice. Moreover, the immunized mice also developed antibodies against some other lupus antigens than on native dsDNA. This feature most probably results from the conformational changes of ds to ssDNA that allow and Ig deposition was present in renal glomeruli (36) . We could also demonstrate in this study that a peptide surrogate the antibody to bind exposed regions of single strandedness (24) that are normally masked by the dsDNA helix structure.
identified from a phage peptide library using anti-dsDNA antibodies in SLE sera has the same antigenic structure Alternatively, the small molecule of phage ssDNA exhibited more binding sites than the large molecule of human placenta with DNA and native RNA, and induced anti-DNA antibody production in rabbits. These studies suggest that DNA antigen ss and dsDNAs when they were applied at the same amount, molecules for anti-double-stranded DNA antibodies.
is not indispensable for the production of anti-DNA antibodies. As such, our second goal of the project is to attempt
